Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer.
Colorectal cancer (CRC) represents the third most common type of cancer in developed countries and one of the leading causes of cancer deaths worldwide. Personalized management of CRC has gained increasing attention since there are large inter-individual variations in the prognosis and response to drugs used to treat CRC owing to molecular heterogeneity. Approximately 15% of CRCs are caused by deficient mismatch repair (dMMR) characterized by microsatellite instability (MSI) phenotype. The present review is aimed at highlighting the role of MMR status in informing prognosis and personalized treatment of CRC including adjuvant chemotherapy, targeted therapy, and immune checkpoint inhibitor therapy to guide the individualized therapy of CRC.
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China. ZhangCM126126@126.com.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China. ZhangCM126126@126.com.
Cong-Min
CM
Zhang
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, China. lvjinfeng1990@163.com.|Institute of Hospital Pharmacy, Central South University, Changsha 410008, China. lvjinfeng1990@163.com.
Jin-Feng
JF
Lv
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China. gongliang3991@163.com.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China. gongliang3991@163.com.
Liang
L
Gong
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China. yulinhui19910530@163.com.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China. yulinhui19910530@163.com.
Lin-Yu
LY
Yu
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China. chenxp74@hotmail.com.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China. chenxp74@hotmail.com.
Xiao-Ping
XP
Chen
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China. hhzhou2003@163.com.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China. hhzhou2003@163.com.
Hong-Hao
HH
Zhou
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China. fanlan_038038@163.com.|Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China. fanlan_038038@163.com.
Lan
L
Fan
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D053843:DNA Mismatch Repair; D006801:Humans; D053842:Microsatellite Instability; D057285:Precision Medicine; D011379:Prognosis
D000970:Antineoplastic Agents
adjuvant chemotherapy; colorectal cancer; immune checkpoint inhibitor therapy; microsatellite instability; mismatch repair system; personalized treatment; targeted therapy